Editorial & Content Integrity Policy
Standards for medical accuracy, evidence-based information, and editorial integrity across HIV, Hepatitis C, weight management, and anticoagulant content.
Editorial Mission
SunnyPharma® is a global, independent educational platform that provides patients and caregivers with medically accurate, transparently sourced, and clearly written content on HIV treatment, Hepatitis C therapy, weight management medications, and anticoagulant therapy. Our goal is to help readers understand treatment options, medication access, and healthcare decisions through clear, evidence-based educational content.
All information on this website is provided for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Readers should always consult a licensed healthcare professional in their own country before making any medical decision.
Editorial Principles
Every editorial decision at SunnyPharma® is guided by six core principles. These principles govern what we cover, how we write it, who reviews it, and how we respond when information changes.
Clinical claims are drawn from primary evidence and reviewed by qualified healthcare professionals before publication. Accuracy takes precedence over engagement, brevity, or commercial interest.
Editorial decisions are made by the SunnyPharma® editorial team. No pharmaceutical manufacturer, advertiser, or commercial partner directs what we cover or how we describe it.
We disclose who writes and reviews our content, how the platform is funded, and when content was last updated. Readers should never have to guess about our process or our interests.
Medical knowledge evolves. We review drug and treatment content on a structured schedule and update it when new regulatory labeling, guidelines, or clinical evidence becomes available.
Clinical information is written for patients and caregivers first. We use plain language, careful framing, and clear structure so that readers across a range of health literacy can understand what they read.
We correct errors promptly and visibly. We do not silently remove or rewrite content to conceal mistakes. When we are wrong, we say so, explain the correction, and improve our process.
1. Purpose & Scope
This Editorial Policy governs all health, pharmaceutical, and clinical content published on sunnypharma.info. It applies to condition guides, drug information pages, FAQ sections, news articles, blog posts, patient resources, and any other written or multimedia content accessible to the public.
This policy exists to support the goal that every piece of content is medically accurate and evidence-based, to help protect patients from misinformation about medications, dosing, and safety, and to build and maintain the trust of patients, caregivers, and healthcare providers worldwide.
2. Editorial Independence
SunnyPharma®’s editorial content is produced independently and is not directed by pharmaceutical manufacturers, distributors, or commercial partners. Any discussion of medication pricing, access programs, or treatment options is provided strictly for informational and educational purposes and is not an offer, recommendation, or facilitation of any purchase.
SunnyPharma® has no affiliate, referral-commission, or sponsorship relationships and earns no commission from any organization referenced in its content. See Section 13: Funding & Commercial Transparency for details.
2.1 Separation of Content and Commerce
Editorial content is created and reviewed by qualified medical professionals. Commercial partners do not direct, alter, or withhold editorial content. Sponsored or partner content, if ever published, will be clearly and prominently labeled as such and held to the same medical-accuracy standards as original editorial content.
2.2 Editorial Conflicts of Interest
Contributors, reviewers, and editors are required to disclose any financial, professional, or personal relationship that could constitute a conflict of interest with respect to content they author or review. Undisclosed conflicts of interest are grounds for removal of the affected content and for disqualification from the editorial process.
3. Global Audience & Regional Differences
SunnyPharma® serves a global readership. Medications, brand names, approved indications, regulatory labeling, pricing, and patient-assistance programs differ significantly from one country to another, and information that is accurate in one jurisdiction may not apply in another.
For this reason, our content references globally authoritative health authorities and clinical guidelines, and readers are directed to rely on the official sources, regulations, and qualified healthcare professionals in their own country. Where our content describes treatments, access pathways, or assistance programs, readers should confirm what applies to them through the relevant authority in their own jurisdiction before acting on any information.
4. Content Lifecycle
Every piece of content on sunnypharma.info follows a defined lifecycle from initial brief to eventual retirement or replacement. This is intended to ensure that nothing is published without review, and nothing remains live without periodic verification.
- Topic Selection & Brief — The editorial team identifies content needs based on patient information needs, clinical relevance, and gaps in current coverage. Topics are approved before any writing begins.
- Research & Drafting — A qualified health writer or researcher drafts content using primary evidence sources: regulatory drug labeling, recognized clinical guidelines, and peer-reviewed literature.
- Medical Review — A qualified physician reviews the article for clinical accuracy and appropriate context. Reviewer specialty is matched to the content area where available (see Section 6: Medical Review Board).
- Editorial QA & Publication — A senior editor performs a final review for readability, compliance with this policy, citation formatting, and technical accuracy before publishing.
- Scheduled Review — Published content enters a review cycle. Drug pages are reviewed every 6 months; condition guides annually; pricing information quarterly (see Section 10: Content Updates & Corrections).
- Update or Retirement — Content is updated in-line with a visible correction or review notice, or retired and redirected if superseded by newer, more complete content.
5. Medical Review Process
Health, clinical, and pharmaceutical content published on sunnypharma.info is intended to undergo a structured review process before publication.
A qualified health writer or researcher drafts content based on primary evidence sources — regulatory drug labeling, clinical guidelines, and peer-reviewed literature.
A qualified physician reviews the article for medical accuracy, appropriate language, and clinical context. Where available, reviewer specialty is matched to the content area — for HIV content: HIV Medicine Specialist or Infectious Disease physician; for Hepatitis C: Gastroenterologist or Hepatologist; for weight management: Endocrinologist or Obesity Medicine specialist; for anticoagulant content: Cardiologist or Hematologist.
A senior editor performs a final review for readability, compliance with this policy, proper citation formatting, and adherence to our style guide before publishing.
5.1 Reviewer Credentials
Medical reviewers are required to hold current, valid licensure in their jurisdiction. Accepted credentials include a physician qualification (such as M.D. or D.O.) with relevant specialty experience, or another licensed clinical credential appropriate to the content under review. Credentials are verified prior to engagement, and reviewer information is displayed on applicable content pages so readers can assess the authorship and currency of what they read.
5.2 Reviewer Disclosure
Each piece of reviewed content displays a byline including the reviewer’s name, professional credentials, specialty, and the date of medical review. Reviewers are required to disclose any financial relationships with pharmaceutical manufacturers relevant to the content being reviewed.
6. Medical Review Board
6.1 Purpose
SunnyPharma® maintains a Medical Review Board composed of licensed healthcare professionals and subject-matter experts who provide clinical oversight for health information published on sunnypharma.info. The Board is intended to help ensure that educational content discussing medications, treatment guidelines, and disease management reflects current clinical evidence and accepted medical practice.
- Medical accuracy and clinical correctness
- Appropriate clinical context for the intended audience
- Clarity and accessibility for patient readers
- Alignment with recognized treatment guidelines (such as DHHS, AASLD, IDSA, EACS, Endocrine Society, ACC/AHA, and CHEST)
6.2 Areas of Expertise
Reviewers contributing to SunnyPharma® content may include professionals with experience in infectious disease medicine and HIV treatment, antiretroviral therapy and HIV pharmacology, hepatology and Hepatitis C management, endocrinology and obesity medicine, and cardiology and hematology for anticoagulant therapy. Reviewers provide guidance only within their area of expertise.
6.3 Role of Medical Reviewers
Medical reviewers provide editorial oversight and factual verification but do not provide patient-specific medical advice. Their role includes reviewing clinical claims for accuracy, verifying dosing and safety information against approved regulatory labeling, confirming alignment with major clinical guidelines, and recommending updates when new evidence becomes available.
6.4 Contributor Engagement
SunnyPharma®’s writers, medical reviewers, and editorial staff are independent professionals engaged on a contract basis. They are not employees of SunnyPharma®. Contributors are identified, credential-verified, and engaged through third-party organizations that specialize in sourcing and vetting qualified medical writers and clinical reviewers. Regardless of the engaging organization, every writer and reviewer is bound by this Editorial Policy — including its accuracy standards, disclosure requirements, and conflict-of-interest rules — and editorial control over all published content remains solely with SunnyPharma®.
No Patient-Provider Relationship. Participation by a medical reviewer does not create a doctor–patient relationship with readers. All information on sunnypharma.info is for educational purposes only and should not replace consultation with a licensed healthcare professional in your own country.
7. Content Categories & Specific Standards
7.1 HIV Treatment Content
Content covering HIV antiretroviral therapy — including medications such as Biktarvy, Descovy, Tivicay, Triumeq, Truvada, Reyataz, and Prezista — must accurately represent indication (treatment vs. PrEP) without conflating the two, reference current treatment guidelines from recognized authorities (such as the DHHS Adult and Adolescent ARV Treatment Guidelines and the European AIDS Clinical Society Guidelines), use person-first destigmatizing language consistent with WHO, UNAIDS, and CDC recommendations, clearly note the requirement for a valid prescription and ongoing clinical monitoring, and not make therapeutic-equivalence claims between branded and generic formulations without regulatory citation.
7.2 Hepatitis C Treatment Content
Hepatitis C treatment content must reference current AASLD/IDSA HCV Guidance and equivalent international guidance (such as EASL) as authoritative clinical standards, correctly distinguish between genotype-specific and pangenotypic regimens, and accurately represent cure rates (SVR12) from clinical trial data only — no extrapolation without citation.
7.3 Weight Management Medication Content
Content covering weight management medications must comply with applicable advertising standards for health claims, accurately represent approved indications and contraindications, not imply results beyond those demonstrated in controlled clinical trials, and always include a recommendation to consult a physician before initiating treatment.
7.4 Pricing & Cost Information
All pricing information must be clearly dated, accompanied by a note that prices vary by country and are subject to change, and verified for accuracy on a minimum quarterly basis. Comparative pricing claims must use current, verifiable reference prices and identify the country to which they apply.
7.5 Anticoagulant Medication Content
Content covering anticoagulant medications — specifically the direct oral anticoagulants Xarelto (rivaroxaban) and Eliquis (apixaban) — must reference current clinical guidance appropriate to the indication: the ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation and equivalent international guidance for stroke-prevention contexts, and the CHEST Guideline on Antithrombotic Therapy for VTE Disease for venous thromboembolism, deep vein thrombosis, and pulmonary embolism contexts. Anticoagulant content must clearly distinguish between indications without conflating them, accurately represent approved regulatory labeling for dosing and contraindications, prominently note bleeding risk and the requirement that any decision to start, stop, or change anticoagulant therapy be made only with a licensed prescriber, and avoid therapeutic-equivalence or comparative-superiority claims between agents absent a regulatory or guideline citation.
8. Sourcing & Citation Standards
All factual and clinical claims in published content must be supported by in-text citations linked to primary or secondary sources. Citations must link directly to the source document (such as a PubMed abstract, a regulatory label page, or an official guideline document). Sources must be dated within the last five years for clinical content, unless referencing foundational pharmacology data. Secondary aggregators are not permitted as sole sources for clinical claims. A minimum of three credible sources is required for any standalone clinical article.
9. Evidence Standards & Medical Sources
SunnyPharma® applies a strict evidence hierarchy to every clinical claim. Because our readership is global, we reference the official drug regulators and recognized clinical guidelines across major jurisdictions. The hierarchy below defines which sources are authoritative for drug information, treatment guidance, and outcome data published on this platform.
| Priority | Source Type | Examples |
|---|---|---|
| 1st — Gold Standard | Official regulator-approved prescribing information and drug monographs | U.S. FDA, Health Canada, UK MHRA, European Medicines Agency (EMA), Australia TGA, Mexico COFEPRIS |
| 2nd — Clinical Guidelines | National and international treatment guidelines from recognized health authorities | WHO, DHHS HIV Guidelines, EACS, AASLD/IDSA & EASL HCV Guidance, Endocrine Society, ACC/AHA/ACCP/HRS Atrial Fibrillation Guideline, CHEST VTE Guideline, CDC, ECDC |
| 3rd — Peer-Reviewed Research | Primary research published in indexed, peer-reviewed journals | PubMed-indexed RCTs, systematic reviews, and meta-analyses |
| 4th — Established Medical Institutions | Reputable clinical reference platforms and academic medical centers | NIH, Mayo Clinic, Johns Hopkins Medicine, UCSF, UpToDate, Medscape |
| Not Permitted | Unverified secondary sources | Wikipedia, unverified blogs, patient forums, manufacturer promotional materials as standalone sources |
9.1 Guideline Currency
Clinical guidelines are updated regularly by their issuing bodies. SunnyPharma® monitors for guideline updates in its key therapeutic areas and aims to initiate content review within 30 days of a significant guideline change. The principal guidelines governing each therapeutic area include:
- HIV treatment: DHHS Adult and Adolescent ARV Treatment Guidelines and the European AIDS Clinical Society (EACS) Guidelines
- Hepatitis C treatment: AASLD/IDSA HCV Guidance and EASL Clinical Practice Guidelines
- Weight management: Endocrine Society Clinical Practice Guidelines and recognized international guidance on GLP-1 medications
- Anticoagulant therapy: ACC/AHA/ACCP/HRS Guideline for Atrial Fibrillation (stroke-prevention indications) and the CHEST Guideline on Antithrombotic Therapy for VTE Disease (venous thromboembolism indications)
9.2 Regulatory Label Changes
When a recognized regulator approves a label change for any drug covered on sunnypharma.info — including new indications, safety-warning updates, new contraindications, or revised dosing — the relevant content is flagged for review, updated promptly (target: within 14 days), and the update is recorded in our Content Audit Log with a visible correction notice on the affected page.
10. Content Updates, Corrections & Retractions
Medical information evolves. SunnyPharma® keeps content current and corrects errors promptly and transparently.
10.1 Regular Content Reviews
| Content Type | Minimum Review Frequency |
|---|---|
| Drug information pages | Every 6 months, or promptly on a new regulatory label update |
| Clinical condition guides | Annually |
| Blog articles & news | Annually, or when referenced guidelines are updated |
| Pricing information | Quarterly minimum, or promptly on a price change |
10.2 Corrections Policy
If factual errors are identified in published content — whether discovered internally or reported by readers — SunnyPharma® will: (1) investigate promptly, (2) publish a transparent correction notice at the top of the affected page, (3) update all relevant citations, and (4) document the correction in our internal Content Audit Log. We do not silently edit content to conceal errors. Readers are encouraged to report inaccuracies via our Contact page.
10.3 Content Dating & Transparency
Health and clinical content on sunnypharma.info displays three dates where applicable: original publication date, medical review date, and last updated date — so readers can see when content was published, reviewed, and last updated.
11. External Links & Third-Party Resources
SunnyPharma® may reference or link to third-party organizations, government agencies, non-profit resources, and patient-assistance programs. These references are provided for information only.
When a reader follows a link to a third-party website, they leave sunnypharma.info. SunnyPharma® does not operate, control, or monitor those websites or organizations and is not responsible for their content, accuracy, availability, services, or practices, or for any interaction, decision, or outcome that follows from using them. The inclusion of any organization or link does not constitute an endorsement, recommendation, or guarantee of any service, and SunnyPharma® receives no compensation for any reference or link. Readers are responsible for reviewing the terms, privacy practices, and applicable regulations of any third party they choose to engage, and should confirm what applies in their own country.
12. Audience Considerations
SunnyPharma® content serves a dual audience: patients and caregivers seeking medication information, and healthcare providers seeking clinical reference material. Content is clearly differentiated by audience where applicable.
- Patient-facing content uses accessible language and focuses on practical information: cost, access, side-effect management, and adherence
- Clinical reference content uses appropriate medical terminology and links directly to primary literature
- All content maintains sensitivity to the emotional and social dimensions of HIV, Hepatitis C, weight management, and anticoagulant therapy — conditions and treatments often accompanied by stigma, anxiety, and complex socioeconomic factors
13. Funding & Commercial Transparency
SunnyPharma® is transparent about how the platform is funded and how any commercial relationships are managed.
13.1 Independent Editorial Content
All editorial content on sunnypharma.info is created independently. No commercial relationship influences the selection of topics covered, the accuracy of clinical information presented, the conclusions reached in educational content, or the inclusion or exclusion of specific medications. Editorial decisions are made solely by the SunnyPharma® editorial team.
13.2 No Affiliate or Referral-Commission Relationships
SunnyPharma® does not currently earn referral or affiliate commissions, and no commercial partner pays for editorial coverage, product placement, or inclusion in our content. Where our content references patient-assistance programs, non-profit resources, public directories, or other pathways to care, those references are informational only and are not endorsements. If SunnyPharma® enters any referral or affiliate relationship in the future, that relationship will be clearly disclosed on the relevant page before any such link is used, and it will not affect the clinical accuracy or editorial conclusions of our content.
13.3 No Pharmaceutical Manufacturer Sponsorship
SunnyPharma® does not accept payment from pharmaceutical manufacturers in exchange for editorial coverage, favorable product descriptions, or preferential placement within educational content. Medication information is based on approved regulatory prescribing information, recognized clinical guidelines, and peer-reviewed medical research.
13.4 Advertising and Sponsored Content
If advertising or sponsored content is ever displayed on sunnypharma.info, it will be clearly labeled, visually distinct from editorial material, and will not be presented as medical advice or an editorial recommendation. Sponsored material must still comply with the accuracy and safety standards described in this policy.
14. Policy Governance & Review
This Editorial Policy is owned by the SunnyPharma® Editorial Director and reviewed annually, or sooner in the event of significant regulatory changes or substantive changes to the clinical guidelines governing our key therapeutic areas.
All staff, contractors, and third-party contributors involved in content creation or review for sunnypharma.info must acknowledge and agree to this policy prior to engagement. Questions regarding this policy should be directed to the editorial team via the Contact page.
Questions about this policy? Contact our editorial team via the Contact page. We aim to review all policy enquiries within five business days.